Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has drawn a 'Buy' rating from Rodman & Renshaw, which initiated coverage with an $8.00 price target based on the company's lead drug candidate, Lucid-MS. The candidate is described as a potentially first-in-class non-immunomodulatory small molecule designed to address neurodegeneration and disability progression in progressive multiple sclerosis (MS), a condition where therapeutic options remain limited. The rating and price target reflect the firm's valuation of the company's development pipeline.
The news underscores the importance of Lucid-MS, which is being developed through Quantum's wholly owned subsidiary, Lucid Psycheceuticals Inc. Lucid-MS is a patented new chemical entity that has shown in preclinical models the ability to prevent and reverse myelin degradation, the underlying mechanism of MS. This mechanism of action is particularly significant because current treatments for progressive MS often focus on immunomodulation, leaving a gap for therapies that directly target neurodegeneration and disability progression.
The initiation of coverage by Rodman & Renshaw brings additional attention to Quantum BioPharma's pipeline, which also includes candidates for neurodegenerative and metabolic disorders as well as alcohol misuse disorders. The company's strategic moves, such as spinning out the OTC version of its UNBUZZD product to Unbuzzd Wellness Inc. (UWI), have also been part of its broader business model. Quantum retains a 19.48% ownership stake in UWI (as of June 30, 2026) and is entitled to royalty payments of 7% of sales from UNBUZZD until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains full rights to develop similar products for pharmaceutical and medical uses.
This development is important for investors and the biotech industry as it highlights the potential of a non-immunomodulatory approach to treating progressive MS, a patient population with high unmet need. The analyst's valuation provides a benchmark for investors assessing the company's potential. For more information on Lucid-MS, visit https://nnw.fm/8uqwL. The latest news and updates on QNTM are available at https://nnw.fm/QNTM.
As with any biotech investment, risks remain, including clinical trial outcomes and regulatory approvals. However, the 'Buy' rating and price target from Rodman & Renshaw add to the growing interest in Quantum BioPharma's pipeline and its potential to address significant unmet medical needs.
